EP0455119A2 - Process for the preparation of canthaxanthin and astaxanthin - Google Patents

Process for the preparation of canthaxanthin and astaxanthin Download PDF

Info

Publication number
EP0455119A2
EP0455119A2 EP91106567A EP91106567A EP0455119A2 EP 0455119 A2 EP0455119 A2 EP 0455119A2 EP 91106567 A EP91106567 A EP 91106567A EP 91106567 A EP91106567 A EP 91106567A EP 0455119 A2 EP0455119 A2 EP 0455119A2
Authority
EP
European Patent Office
Prior art keywords
general formula
formula
reacted
canthaxanthin
triphenylphosphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91106567A
Other languages
German (de)
French (fr)
Other versions
EP0455119A3 (en
Inventor
Hansgeorg Dr. Ernst
Joachim Dr. Paust
Werner Dr. Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP0455119A2 publication Critical patent/EP0455119A2/en
Publication of EP0455119A3 publication Critical patent/EP0455119A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • C07F9/5435Cycloaliphatic phosphonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • the invention relates to a new process for the preparation of the sought-after carotenoids canthaxanthin (Ia) and astaxanthin (Ib).
  • the halides of the formula below are used as C15-phosphonium salts, the bromide in particular being used as the anion of the phosphonium salt.
  • the phosphonium salts suitable according to the above-described synthesis principle C15 + C10 + C1 nach as C15 building blocks for canthaxanthin or astaxanthin are obtained by reacting the corresponding allyl bromides of the formula made with triphenylphosphine.
  • butylene oxide In the further processing of the allyl bromide, butylene oxide must also be added several times to trap acid traces.
  • the tertiary alcohol of the formula IIa is converted by treatment with phosphorus tribromide in an inert organic solvent into the corresponding allyl bromide, from which the corresponding phosphonium salt is obtained by reaction with triphenylphosphine (DE-OS 2 801 908) .
  • triphenylphosphine DE-OS 2 801 908
  • a considerable excess ⁇ 3 equivalents
  • the triphenylphosphonium bromide can also be prepared directly from the tertiary alcohol of the formula IIa by reaction with triphenylphosphine hydrobromide (cf. DE-OS 2 801 908).
  • this reagent must be prepared in an additional step from triphenylphosphine and HBr and must also be used in a considerable excess.
  • the invention also relates to the new intermediates of the formulas III and IV which enable the advantageous new process.
  • the reaction of the tertiary alcohols of the formula II with trifluoroacetic acid is generally carried out in an inert organic solvent, such as methylene chloride, 1,2-dichloroethane or ethyl acetate, at temperatures from about 0 ° C. to + 50 ° C., preferably 10-30 ° C., in particular at room temperature. Only 1.0-1.05 equivalents of trifluoroacetic acid, based on the alcohols of the formula II, are required here.
  • the new trifluoroacetates of the formula III are obtained in a smooth reaction and in good yields, without the secondary hydroxyl group of IIIb being esterified and without the risk that the ⁇ -ketol is rearranged into the diosphenol.
  • the crude trifluoroacetates of the formula III can be further processed directly to the phosphonium salts of the formula IV, for example by heating with a triarylphosphine, in particular triphenylphosphine, in an inert organic solvent such as toluene, ethyl acetate or methylene chloride.
  • a triarylphosphine in particular triphenylphosphine
  • an inert organic solvent such as toluene, ethyl acetate or methylene chloride.
  • the triphenylphosphine is generally used in amounts of 1.0 to 1.2 moles per mole of trifluoroacetate of the formula III.
  • the reaction is generally carried out at from room temperature to the reflux temperature of the solvent used, preferably at from about 50 to 100.degree.
  • the reaction time is, for example, about 15 to 30 minutes when the reaction is carried out without a solvent in the temperature range from 80 to 100 ° C.
  • the crude phosphonium salt of the formula IV obtained in this way can be purified by precipitation from a suitable organic solvent, such as methyl tert-butyl ether (MTB) or diisopropyl ether.
  • a suitable organic solvent such as methyl tert-butyl ether (MTB) or diisopropyl ether.
  • carotenoids canthaxanthin Ia are obtained from the phosphonium salts of the formula IVa or IVb by reaction with the C10 dialdehyde 2,7-dimethyl-2,4,6-octatriene-1,8-dial under the reaction conditions typical of such Wittig condensations or astaxanthin Ib in good yields.
  • the phosphonium salt IVb was obtained in the form of colorless crystals by redissolving in ethyl acetate and dropwise adding MTB. Mp .: 147-148 ° C, calculated fluorine value: 9.4%, analytically determined fluorine value: 9.5%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Process for the preparation of canthaxanthine (Ia) and astaxanthine (Ib) of the general formula I …<IMAGE>… in which R represents H (a) or OH (b), which process is characterised in that a tertiary alcohol of the general formula II …<IMAGE>… in which R represents H (a) or OH (b), is reacted with trifluoroacetic acid, the novel trifluoroacetate obtained of the general formula III …<IMAGE>… is reacted with triphenylphosphine, the novel triphenylphosphonium trifluoroacetate obtained of the general formula IV …<IMAGE>… is reacted with 2,7-dimethyl-2,4,6-octatriene-1,8-dial under the conditions of a Wittig synthesis. In addition, the invention relates to the novel trifluoroacetates of the formula III and the corresponding triphenylphosphonium trifluoroacetates of the formula IV.

Description

Die Erfindung betrifft ein neues Verfahren zur Herstellung der begehrten Carotinoide Canthaxanthin (Ia) und Astaxanthin (Ib).The invention relates to a new process for the preparation of the sought-after carotenoids canthaxanthin (Ia) and astaxanthin (Ib).

Ein mehrfach beschriebenes Synthesekonzept für diese beiden Carotinoide beruht auf der zweifachen Wittig-Kondensation eines entsprechenden C₁₅-Phosphoniumsalzes mit dem symmetrischen C₁₀-Dialdehyd 2,7-Dimethyl-2,4,6-octatrien-1,8-dial.A repeatedly described synthesis concept for these two carotenoids is based on the double Wittig condensation of a corresponding C₁ eines-phosphonium salt with the symmetrical C₁₀-dialdehyde 2,7-dimethyl-2,4,6-octatrien-1,8-dial.

Nach dem Stand der Technik werden als C₁₅-Phosphoniumsalze die Halogenide der nachstehenden Formel eingesetzt, wobei als Anion des Phosphoniumsalzes insbesondere das Bromid Verwendung findet.

Figure imgb0001
According to the prior art, the halides of the formula below are used as C₁₅-phosphonium salts, the bromide in particular being used as the anion of the phosphonium salt.
Figure imgb0001

Die nach dem oben geschilderten Syntheseprinzip C₁₅+C₁₀+C₁₅ als C₁₅-Bausteine für Canthaxanthin bzw. Astaxanthin geeigneten Phosphoniumsalze werden hierbei durch Umsetzung der entsprechenden Allylbromide der Formel

Figure imgb0002

mit Triphenylphosphin hergestellt.The phosphonium salts suitable according to the above-described synthesis principle C₁₅ + C₁₀ + C₁ nach as C₁₅ building blocks for canthaxanthin or astaxanthin are obtained by reacting the corresponding allyl bromides of the formula
Figure imgb0002

made with triphenylphosphine.

Ein Zugang zu den genannten Allylbromiden besteht in der halogenierenden Allylumlagerung der tertiären Alkohole der Formel II

Figure imgb0003

in der R für H (a) oder OH (b) steht.One access to the allyl bromides mentioned is the halogenating allyl rearrangement of the tertiary alcohols of the formula II
Figure imgb0003

in which R represents H (a) or OH (b).

Dieser in der Literatur mehrfach beschriebene Syntheseweg weist bei der praktischen Durchführung im Hinblick auf verfahrenstechnische Erfordernisse und Wirtschaftlichkeit schwerwiegende Nachteile auf.This synthetic route, which has been described several times in the literature, has serious disadvantages in practical implementation with regard to process engineering requirements and economy.

So muß beispielsweise die Umsetzung des tertiären Alkohols der Formel IIb zu dem entsprechenden Allylbromid bei tiefer Temperatur (gemäß EP 101 597 bei -20°C bis -10°C; EP 5749 bei +5°C und gemäß Helv. chim. acta 64 (1981), Seite 2430 bei 0°C) durch Reaktion mit 63 %iger wäßriger Bromwasserstoffsäure durchgeführt werden, wobei ein erheblicher überschuß an Bromwasserstoff (2,5-4 Äquivalente) benötigt wird. Gemäß Angaben in Helv. chim. acta 64 (1981), Seiten 2430 und 2440, muß die Umsetzung bei tiefer Temperatur und sehr schnell durchgeführt werden, um eine Zersetzung des nicht sehr stabilen Allylbromids zu vermeiden und die Umlagerung des α-Hydroxyketons ins Diosphenol hintan zu halten.For example, the conversion of the tertiary alcohol of the formula IIb to the corresponding allyl bromide at low temperature (according to EP 101 597 at -20 ° C to -10 ° C; EP 5749 at + 5 ° C and according to Helv. Chim. acta 64 (1981), page 2430 at 0 ° C) by reaction with 63% aqueous hydrobromic acid, a considerable excess of hydrogen bromide (2.5-4 equivalents) being required. According to Helv. Chim. acta 64 (1981), pages 2430 and 2440, the reaction must be carried out at low temperature and very quickly in order to avoid decomposition of the not very stable allyl bromide and to keep the rearrangement of the α-hydroxyketone into the diosphenol.

Bei der Weiterverarbeitung des Allylbromids muß zum Abfangen von Säurespuren außerdem mehrmals Butylenoxid zugesetzt werden.In the further processing of the allyl bromide, butylene oxide must also be added several times to trap acid traces.

Zur Herstellung von Canthaxanthin wird nach dem Stand der Technik der tertiäre Alkohol der Formel IIa durch Behandeln mit Phosphortribromid in einem inerten organischen Lösungsmittel in das entsprechende Allylbromid überführt, aus dem durch Umsetzung mit Triphenylphosphin das entsprechende Phosphoniumsalz erhalten (DE-OS 2 801 908) wird. Auch hierbei muß mit einem erheblichen überschuß (≧ 3 Äquivalente) an dem teueren Halogenierungsmittel gearbeitet werden. Alternativ zur Bromierung mit Phosphortribromid und anschließender Umsetzung mit Triphenylphosphin kann man das Triphenylphosphoniumbromid auch direkt aus dem tertiären Alkohol der Formel IIa durch Reaktion mit Triphenylphosphin-Hydrobromid herstellen (vgl. DE-OS 2 801 908). Dieses Reagens muß allerdings in einer zusätzlichen Stufe aus Triphenylphosphin und HBr hergestellt werden und muß gleichfalls in beträchtlichem überschuß eingesetzt werden.For the production of canthaxanthin, the tertiary alcohol of the formula IIa is converted by treatment with phosphorus tribromide in an inert organic solvent into the corresponding allyl bromide, from which the corresponding phosphonium salt is obtained by reaction with triphenylphosphine (DE-OS 2 801 908) . Here too, a considerable excess (≧ 3 equivalents) has to be used on the expensive halogenating agent. As an alternative to bromination with phosphorus tribromide and subsequent reaction with triphenylphosphine, the triphenylphosphonium bromide can also be prepared directly from the tertiary alcohol of the formula IIa by reaction with triphenylphosphine hydrobromide (cf. DE-OS 2 801 908). However, this reagent must be prepared in an additional step from triphenylphosphine and HBr and must also be used in a considerable excess.

In J. Org. Chem. 47 (1982) Seite 2133, wird als beste Herstellungsmethode für dieses C₁₅-Triphenylphosphoniumsalz die Umsetzung des tertiären Alkohols der Formel IIa mit Triphenylphosphin-hydrobromid genannt, wobei das Hydrobromid in einem Überschuß von 17 mol-% eingesetzt wird.In J. Org. Chem. 47 (1982) page 2133, the best production method for this C₁₅-triphenylphosphonium salt is the reaction of the tertiary alcohol of the formula IIa with triphenylphosphine hydrobromide, the hydrobromide being used in an excess of 17 mol% .

Nachteilig an den Verfahren gemäß dem Stand der Technik ist also, daß in jedem Fall für die Umsetzung der tertiären Alkohole der Formel II zu den entsprechenden Triphenylphosphoniumbromiden mit erheblichen überschüssen an teueren und verfahrenstechnisch nicht unproblematischen Halogenierungsmitteln gearbeitet werden muß. Im Falle der Herstellung von Astaxanthin kommt als weiteres Problem die geringe Stabilität entsprechenden Allylbromids hinzu.A disadvantage of the processes according to the prior art is that, in any case, considerable excesses of expensive halogenation agents which are not problematic in terms of process technology must be used for the conversion of the tertiary alcohols of the formula II to the corresponding triphenylphosphonium bromides. In the case of the production of astaxanthin, the low stability of the corresponding allyl bromide is another problem.

Es war daher die Aufgabe der Erfindung, ein Verfahren zur Herstellung von Canthaxanthin und Astaxanthin zu entwickeln, bei dem die Nachteile des Standes der Technik nicht auftreten.It was therefore the object of the invention to develop a process for the production of canthaxanthin and astaxanthin in which the disadvantages of the prior art do not occur.

Es wurde nun überraschenderweise gefunden, daß die tertiären Alkohole der Formel II durch Behandlung mit Trifluoressigsäure glatt in die neuen Trifluoracetate der Formel III und diese durch anschließende Umsetzung mit Triphenylphosphin in die Phosphoniumsalze der Formel IV überführt werden können. Das praktische Vorgehen ist bei beiden Edukten identisch, was einen weiteren erheblichen technischen Vorteil für dieses neue Verfahren bedeutet.It has now surprisingly been found that the tertiary alcohols of the formula II by treatment with trifluoroacetic acid smooth into the new trifluoroacetates of the formula III and these by subsequent reaction with Triphenylphosphine can be converted into the phosphonium salts of formula IV. The practical procedure is identical for both starting materials, which means a further considerable technical advantage for this new process.

Gegenstand der Erfindung ist daher ein Verfahren zur Herstellung von Canthaxanthin (Ia) und Astaxanthin (Ib) der allgemeinen Formel I

Figure imgb0004

in der R für H (a) oder OH (b) steht, das dadurch gekennzeichnet ist, daß man

  • A. einen tertiären Alkohol der allgemeinen Formel II
    Figure imgb0005
    in der R für H (a) oder OH (b) steht, mit Trifluoressigsäure umsetzt,
  • B. das erhaltene neue Trifluoracetat der allgemeinen Formel III
    Figure imgb0006
    mit Triphenylphosphin umsetzt,
  • C. das erhaltene neue Triphenylphosphoniumtrifluoracetat der allgemeinen Formel IV
Figure imgb0007

in der R für H (a) oder OH (b) steht,
mit 2,7-Dimethyl-2,4,6-octatrien-1,8-dial unter den Bedingungen einer Wittigsynthese umsetzt.The invention therefore relates to a process for the preparation of canthaxanthin (Ia) and astaxanthin (Ib) of the general formula I.
Figure imgb0004

in which R represents H (a) or OH (b), which is characterized in that
  • A. a tertiary alcohol of the general formula II
    Figure imgb0005
    in which R represents H (a) or OH (b), reacted with trifluoroacetic acid,
  • B. the new trifluoroacetate obtained of the general formula III
    Figure imgb0006
    reacted with triphenylphosphine,
  • C. the new triphenylphosphonium trifluoroacetate obtained of the general formula IV
Figure imgb0007

in which R represents H (a) or OH (b),
reacted with 2,7-dimethyl-2,4,6-octatriene-1,8-dial under the conditions of a Wittigsynthesis.

Gegenstand der Erfindung sind außerdem die neuen Zwischenprodukte der Formeln III und IV, die das vorteilhafte neue Verfahren ermöglichen.The invention also relates to the new intermediates of the formulas III and IV which enable the advantageous new process.

Die Umsetzung der tertiären Alkohole der Formel II mit Trifluoressigsäure wird im allgemeinen in einem inerten organischen Lösungsmittel, wie Methylenchlorid, 1,2-Dichlorethan oder Essigsäureethylester bei Temperaturen von etwa 0°C bis +50°C, vorzugsweise 10-30°C, insbesondere bei Raumtemperatur, durchgeführt. Es werden hierbei nur 1,0-1,05 Äquivalente an Trifluoressigsäure, bezogen auf die Alkohole der Formel II benötigt. Man erhält in glatter Reaktion und in guten Ausbeuten die neuen Trifluoracetate der Formel III, ohne daß die sekundäre Hydroxygruppe von IIIb verestert wird und ohne Gefahr, daß das α-Ketol ins Diosphenol umlagert wird.The reaction of the tertiary alcohols of the formula II with trifluoroacetic acid is generally carried out in an inert organic solvent, such as methylene chloride, 1,2-dichloroethane or ethyl acetate, at temperatures from about 0 ° C. to + 50 ° C., preferably 10-30 ° C., in particular at room temperature. Only 1.0-1.05 equivalents of trifluoroacetic acid, based on the alcohols of the formula II, are required here. The new trifluoroacetates of the formula III are obtained in a smooth reaction and in good yields, without the secondary hydroxyl group of IIIb being esterified and without the risk that the α-ketol is rearranged into the diosphenol.

Die rohen Trifluoracetate der Formel III können direkt zu den Phosphonium-salzen der Formel IV weiterverarbeitet werden, beispielsweise durch Erhitzen mit einem Triarylphosphin, insbesondere Triphenylphosphin, in einem inerten organischen Lösungsmittel wie Toluol, Essigester oder Methylenchlorid. Besonders einfach läßt sich diese Umsetzung durchführen, indem man die rohen Trifluoracetate in Substanz ohne Zusatz eines Lösungsmittels mit Triphenylphosphin erhitzt.The crude trifluoroacetates of the formula III can be further processed directly to the phosphonium salts of the formula IV, for example by heating with a triarylphosphine, in particular triphenylphosphine, in an inert organic solvent such as toluene, ethyl acetate or methylene chloride. This reaction can be carried out particularly easily by heating the crude trifluoroacetates in bulk without the addition of a solvent with triphenylphosphine.

Das Triphenylphosphin verwendet man hierbei im allgemeinen in Mengen von 1,0 bis 1,2 Mol pro Mol Trifluoracetat der Formel III. Die Umsetzung erfolgt im allgemeinen bei Temperaturen von Raumtemperatur bis Rückflußtemperatur des verwendeten Lösungsmittels, vorzugsweise bei Temperaturen von etwa 50 bis 100°C. Die Reaktionszeit beträgt beispielsweise bei der Durchführung der Umsetzung ohne Lösungsmittel im Temperaturbereich von 80 bis 100°C etwa 15 bis 30 Minuten.The triphenylphosphine is generally used in amounts of 1.0 to 1.2 moles per mole of trifluoroacetate of the formula III. The reaction is generally carried out at from room temperature to the reflux temperature of the solvent used, preferably at from about 50 to 100.degree. The reaction time is, for example, about 15 to 30 minutes when the reaction is carried out without a solvent in the temperature range from 80 to 100 ° C.

Das so erhaltene rohe Phosphoniumsalz der Formel IV kann durch Fällung aus einem geeigneten organischen Lösungsmittel, wie Methyl-tert.-butylether (MTB) oder Diisopropylether, gereinigt werden.The crude phosphonium salt of the formula IV obtained in this way can be purified by precipitation from a suitable organic solvent, such as methyl tert-butyl ether (MTB) or diisopropyl ether.

Aus den Phosphoniumsalzen der Formel IVa bzw. IVb erhält man durch Umsetzung mit dem C₁₀-Dialdehyd 2,7-Dimethyl-2,4,6-octatrien-1,8-dial unter den für solche Wittig-Kondensationen typischen Reaktionsbedingungen die Carotinoide Canthaxanthin Ia bzw. Astaxanthin Ib in guten Ausbeuten.The carotenoids canthaxanthin Ia are obtained from the phosphonium salts of the formula IVa or IVb by reaction with the C₁₀ dialdehyde 2,7-dimethyl-2,4,6-octatriene-1,8-dial under the reaction conditions typical of such Wittig condensations or astaxanthin Ib in good yields.

Bezüglich näherer Einzelheiten über die Reaktionsbedingungen für Wittig-Reaktionen verweisen wir beispielsweise auf J. Org. Chem. 47 (1982) Seiten 2130-2134 und Helv. Chim. Acta 64 (1981) Seiten 2436ff.For more details on the reaction conditions for Wittig reactions, we refer, for example, to J. Org. Chem. 47 (1982) pages 2130-2134 and Helv. Chim. Acta 64 (1981) pages 2436ff.

Die folgenden Beispiele sollen das erfindungsgemäße Verfahren erläutern.The following examples are intended to explain the process according to the invention.

Beispiel 1example 1 A. Herstellung von 5-[2,6,6-Trimethyl-3-oxo-1-cyclohexen-1-yl]-3-methyl-2,4-pentadien-1-ol-trifluoroacetat (IIIa)A. Preparation of 5- [2,6,6-trimethyl-3-oxo-1-cyclohexen-1-yl] -3-methyl-2,4-pentadien-1-ol-trifluoroacetate (IIIa)

10,0 g (42,7 mmol) 5-[2,6,6-Trimethyl-3-oxo-1-cyclohexen-1-yl]-3-methyl-3-hydroxy-1,4-pentadien (IIa) wurden in 40 ml Methylenchlorid gelöst und hierzu bei 0°C 4,4 ml (43,2 mmol) Trifluoressigsäure (D 1,12) zugetropft. Anschließend ließ man das Reaktionsgemisch auf Raumtemperatur (RT) kommen und rührte 3 Stunden (h) bei RT nach.10.0 g (42.7 mmol) 5- [2,6,6-trimethyl-3-oxo-1-cyclohexen-1-yl] -3-methyl-3-hydroxy-1,4-pentadiene (IIa) were dissolved in 40 ml of methylene chloride and 4.4 ml (43.2 mmol) of trifluoroacetic acid (D 1.12) were added dropwise at 0.degree. The reaction mixture was then allowed to come to room temperature (RT) and stirred at RT for 3 hours (h).

Danach wurde der Ansatz auf Wasser gegossen. Die organische Phase wurde abgetrennt und die Wasserphase mit Methylenchlorid nachextrahiert. Die vereinigten organischen Phasen wurden mit verdünnter Natriumhydrogencarbonatlösung gewaschen und über Natriumsulfat getrocknet. Nach dem Abziehen des Lösungsmittels am Rotationsverdampfer erhielt man 12 g des Trifluoracetats IIIa als rötlich gefärbtes Öl. IR-Spektrum (Film): 1784 cm⁻¹ (vs), 1665 cm⁻¹ (s), 1217 cm⁻¹ (vs), 1168 cm⁻¹ (vs).The mixture was then poured onto water. The organic phase was separated off and the water phase was extracted again with methylene chloride. The combined organic phases were washed with dilute sodium hydrogen carbonate solution and dried over sodium sulfate. After the solvent had been stripped off on a rotary evaporator, 12 g of trifluoroacetate IIIa were obtained as a reddish-colored oil. IR spectrum (film): 1784 cm⁻¹ (vs), 1665 cm⁻¹ (s), 1217 cm⁻¹ (vs), 1168 cm⁻¹ (vs).

B. Herstellung von 5-[2,6,6-Trimethyl-3-oxo-1-cyclohexen-1-yl]-3-methyl-2,4-pentadien-1-yl-triphenylphosphonium-trifluoracetat (IVa)B. Preparation of 5- [2,6,6-Trimethyl-3-oxo-1-cyclohexen-1-yl] -3-methyl-2,4-pentadien-1-yl-triphenylphosphonium trifluoroacetate (IVa)

Das rohe Trifluoracetat IIIa wurde zusammen mit 9,5 g Triphenyl-phosphin 30 Minuten (min) im vorgeheizten Ölbad bei einer Bad temperatur von 100-120°C gerührt. Man ließ den Rückstand abkühlen und löste das rohe Phosphoniumsalz in Methylenchlorid auf. Durch Zutropfen dieser Lösung zu Methyl-tert.-butylether (MTB) fiel das Triphenylphosphoniumsalz IVa in Form weißer Kristalle aus. Fp.: 150-154°C

Figure imgb0008
The crude trifluoroacetate IIIa was stirred together with 9.5 g triphenylphosphine for 30 minutes (min) in a preheated oil bath at a bath temperature of 100-120 ° C. The residue was allowed to cool and the crude phosphonium salt was dissolved in methylene chloride. By adding this solution dropwise to methyl tert-butyl ether (MTB), the triphenylphosphonium salt IVa precipitated out in the form of white crystals. Mp .: 150-154 ° C
Figure imgb0008

C. Herstellung von Canthaxanthin (Ia)C. Preparation of canthaxanthin (Ia)

5,3 g des Phosphoniumsalzes IVa und 500 mg 2,7-Dimethyl-2,4,6-octatrien-1,8-dial wurden in 25 ml Methylenchlorid gelöst. Man kühlte auf 0°C ab, tropfte zu der Mischung 1,6 g einer 30 %igen methanolischen Lösung von Natriummethylat zu, ließ auf RT kommen und rührte 2 h nach Danach wurde der Ansatz auf Wasser gegossen. Die organische Phase wurde abgetrennt und die Wasserphase mit Methylenchlorid nachextrahiert. Die vereinigten organischen Phasen wurden über Natriumsulfat getrocknet und am Rotationsverdampfer eingeengt. Der Rückstand wurde mit 20 ml Methanol aufgenommen und 30 min unter Rückfluß zum Sieden erhitzt, dann auf 0°C abgekühlt und das ausgefallene Canthaxanthin abfiltriert.5.3 g of the phosphonium salt IVa and 500 mg of 2,7-dimethyl-2,4,6-octatriene-1,8-dial were dissolved in 25 ml of methylene chloride. The mixture was cooled to 0 ° C., 1.6 g of a 30% strength methanolic solution of sodium methylate were added dropwise to the mixture, the mixture was allowed to come to RT and the mixture was stirred for 2 hours. The mixture was then poured onto water. The organic phase was separated and the water phase was extracted with methylene chloride. The combined organic phases were dried over sodium sulfate and concentrated on a rotary evaporator. The residue was taken up in 20 ml of methanol and heated to boiling under reflux for 30 min, then cooled to 0 ° C. and the precipitated canthaxanthin was filtered off.

Auswaage: 1,1 g CanthaxanthinWeight: 1.1 g canthaxanthin

Durch säulenchromatographische Reinigung der Mutterlauge wurden nochmals 0,4 g Canthaxanthin gewonnen.A further 0.4 g of canthaxanthin was obtained by column chromatography purification of the mother liquor.

Beispiel 2Example 2 A. Herstellung von 5-[2,6,6-Trimethyl-3-oxo-4-hydroxy-1-cyclohexen-1-yl]-3-methyl-2,4-pentadien-1-ol-trifluoroacetat (IIIb)A. Preparation of 5- [2,6,6-trimethyl-3-oxo-4-hydroxy-1-cyclohexen-1-yl] -3-methyl-2,4-pentadien-1-ol-trifluoroacetate (IIIb)

8 g (32 mmol) 5-[2,6,6-Trimethyl-3-oxo-4-hydroxy-1-cyclohexen-1-yl]-3-methyl-3-hydroxy-1,4-pentadien (IIb) wurden in 25 ml Methylenchlorid gelöst. Bei 0°C tropfte man 3,7 g (32,5 mmol) Trifluoressigsäure zu. Man ließ auf RT kommen und rührte 5 h bei RT nach. Dann wurde der Ansatz auf verdünnte Natriumhydrogencarbonatlösung gegossen. Die organische Phase wurde abgetrennt und die Wasserphase mit Methylenchlorid nachextrahiert. Die vereinigten organischen Phasen wurden mit verdünnter Hydrogencarbonatlösung gewaschen und über Natriumsulfat getrocknet. Nach dem Abziehen des Lösungsmittels am Rotationsverdampfer erhielt man 9-10 g des Trifluoracetats IIIb als rohes Öl. IR-Spektrum (Film): 3500 cm⁻¹ (breit), 1784 cm⁻¹ (vs), 1670 cm⁻¹ (s), 1221 cm⁻¹ (s), 1168 cm⁻¹ (vs), 1149 cm⁻¹ (vs).8 g (32 mmol) of 5- [2,6,6-trimethyl-3-oxo-4-hydroxy-1-cyclohexen-1-yl] -3-methyl-3-hydroxy-1,4-pentadiene (IIb) were dissolved in 25 ml of methylene chloride. 3.7 g (32.5 mmol) of trifluoroacetic acid were added dropwise at 0.degree. The mixture was allowed to come to RT and stirred at RT for 5 h. The mixture was then poured onto dilute sodium hydrogen carbonate solution. The organic phase was separated off and the water phase was extracted again with methylene chloride. The combined organic phases were washed with dilute hydrogen carbonate solution and dried over sodium sulfate. After stripping off the solvent on a rotary evaporator, 9-10 g of trifluoroacetate IIIb were obtained as a crude oil. IR spectrum (film): 3500 cm⁻¹ (broad), 1784 cm⁻¹ (vs), 1670 cm⁻¹ (s), 1221 cm⁻¹ (s), 1168 cm⁻¹ (vs), 1149 cm⁻ 1 (vs).

B. Herstellung von 5-[2,6,6-Trimethyl-3-oxo-4-hydroxy-1-cyclohexen-1-yl]-3-methyl-2,4-pentadien-1-yl-triphenylphosphonium-trifluoracetat (IVb)B. Preparation of 5- [2,6,6-Trimethyl-3-oxo-4-hydroxy-1-cyclohexen-1-yl] -3-methyl-2,4-pentadien-1-yl-triphenylphosphonium trifluoroacetate ( IVb)

1,3 g des erhaltenen rohen Trifluoracetats IIIb wurden mit 1,0 g Triphenylphosphin 30 min im vorgeheizten Ölbad bei einer Badtemperatur von 100°C gerührt. Man ließ den Rückstand abkühlen, löste das rohe Phosphoniumsalz in Essigester auf und fällte durch Zutropfen dieser Lösung zu MTB wieder aus. Der Niederschlag wurde abgetrennt und unter vermindertem Druck getrocknet. Man erhielt 1,3-1,4 g des Triphenylphosphoniumsalzes IVb als hellgelben Schaum.1.3 g of the crude trifluoroacetate IIIb obtained were stirred with 1.0 g of triphenylphosphine in a preheated oil bath at a bath temperature of 100 ° C. for 30 minutes. The residue was allowed to cool, the crude phosphonium salt was dissolved in ethyl acetate and the solution was again added dropwise to MTB. The precipitate was separated and dried under reduced pressure. 1.3-1.4 g of the triphenylphosphonium salt IVb were obtained as a light yellow foam.

Durch nochmaliges Auflösen in Essigsäureethylester und Zutropfen von MTB wurde das Phosphoniumsalz IVb in Form farbloser Kristalle erhalten. Fp.: 147-148°C, berechneter Fluorwert: 9,4 %, analytisch bestimmter Fluorwert: 9,5 %.The phosphonium salt IVb was obtained in the form of colorless crystals by redissolving in ethyl acetate and dropwise adding MTB. Mp .: 147-148 ° C, calculated fluorine value: 9.4%, analytically determined fluorine value: 9.5%.

C. Herstellung von Astaxanthin (Ib)C. Preparation of Astaxanthin (Ib)

8,4 g des kristallinen Phosphoniumsalzes IVb und 760 mg 2,7-Dimethyl-2,4,6-octatrien-1,8-dial wurden in 33 ml Methylenchlorid gelöst. Man kühlte auf 0°C ab, tropfte zu der Mischung 2,24 g einer 30 %igen methanolischen Lösung von Natriummethylat zu, ließ die Temperatur auf RT ansteigen und rührte noch 3 1/2 h nach. Danach wurde das Reaktionsgemisch auf Wasser gegossen. Die organische Phase wurde abgetrennt und die Wasserphase mit Methylenchlorid nachextrahiert. Die vereinigten organischen Phasen wurden mit Wasser gewaschen, über Natriumsulfat getrocknet und am Rotationsverdampfer eingeengt. Durch säulenchromatographische Reinigung des Rohproduktes wurde sauberes Astaxanthin gewonnen.8.4 g of the crystalline phosphonium salt IVb and 760 mg of 2,7-dimethyl-2,4,6-octatriene-1,8-dial were dissolved in 33 ml of methylene chloride. The mixture was cooled to 0 ° C., 2.24 g of a 30% strength methanolic solution of sodium methylate was added dropwise to the mixture, the temperature was allowed to rise to RT and the mixture was stirred for a further 3 1/2 hours. The reaction mixture was then poured onto water. The organic phase was separated off and the water phase was extracted again with methylene chloride. The combined organic phases were washed with water, dried over sodium sulfate and concentrated on a rotary evaporator. Clean astaxanthin was obtained by purifying the crude product by column chromatography.

Auswaage: 2,3 g Astaxanthin.Weight: 2.3 g astaxanthin.

Claims (3)

Verfahren zur Herstellung von Canthaxanthin (Ia) und Astaxanthin (Ib) der allgemeinen Formel I
Figure imgb0009
in der R für H (a) oder OH (b) steht, dadurch gekennzeichnet, daß man A. einen tertiären Alkohol der allgemeinen Formel II
Figure imgb0010
in der R für H (a) oder OH (b) steht, mit Trifluoressigsäure umsetzt,
B. das erhaltene neue Trifluoracetat der allgemeinen Formel III
Figure imgb0011
mit Triphenylphosphin umsetzt,
C. das erhaltene neue Triphenylphosphoniumtrifluoracetat der allgemeinen Formel IV
Figure imgb0012
in der R für H (a) oder OH (b) steht,
mit 2,7-Dimethyl-2,4,6-octatrien-1,8-dial unter den Bedingungen einer Wittigsynthese umsetzt.
Process for the preparation of canthaxanthin (Ia) and astaxanthin (Ib) of the general formula I
Figure imgb0009
in which R is H (a) or OH (b), characterized in that A. a tertiary alcohol of the general formula II
Figure imgb0010
in which R represents H (a) or OH (b), reacted with trifluoroacetic acid,
B. the new trifluoroacetate obtained of the general formula III
Figure imgb0011
reacted with triphenylphosphine,
C. the new triphenylphosphonium trifluoroacetate obtained of the general formula IV
Figure imgb0012
in which R represents H (a) or OH (b),
reacted with 2,7-dimethyl-2,4,6-octatriene-1,8-dial under the conditions of a Wittigsynthesis.
Verbindungen der Formel III
Figure imgb0013
in der R für H (a) oder OH (b) steht.
Compounds of formula III
Figure imgb0013
in which R represents H (a) or OH (b).
Verbindungen der Formel IV
Figure imgb0014
in der R für H (a) oder OH (b) steht.
Compounds of formula IV
Figure imgb0014
in which R represents H (a) or OH (b).
EP19910106567 1990-05-03 1991-04-24 Process for the preparation of canthaxanthin and astaxanthin Withdrawn EP0455119A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4014203 1990-05-03
DE4014203A DE4014203A1 (en) 1990-05-03 1990-05-03 METHOD FOR PRODUCING CANTHAXANTHIN AND ASTAXANTHIN

Publications (2)

Publication Number Publication Date
EP0455119A2 true EP0455119A2 (en) 1991-11-06
EP0455119A3 EP0455119A3 (en) 1992-04-15

Family

ID=6405641

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910106567 Withdrawn EP0455119A3 (en) 1990-05-03 1991-04-24 Process for the preparation of canthaxanthin and astaxanthin

Country Status (4)

Country Link
US (1) US5210314A (en)
EP (1) EP0455119A3 (en)
JP (1) JPH04225933A (en)
DE (1) DE4014203A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002881A1 (en) * 1992-07-21 1994-02-03 Basf Aktiengesellschaft Polyenes with non-linear optical properties
EP0633258A1 (en) * 1993-07-05 1995-01-11 BASF Aktiengesellschaft Improved process for the production of astaxanthin, new intermediates therefor and a process for their production
CN1045004C (en) * 1994-03-25 1999-09-08 武田药品工业株式会社 Process for producing carotene compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509955A1 (en) * 1995-03-18 1996-09-19 Basf Ag Process for the production of astaxanthin
EP0978508B1 (en) 1998-08-05 2005-12-14 DSM IP Assets B.V. Preparation of 4,4'-diketo-carotenoids
CL2008001699A1 (en) 2008-06-09 2010-02-05 Univ Chile DNA sequence encoding enzyme with cytochrome p450 reductase activity of x. dendrorhous; encoded polypeptide sequence; vector or plasmid; hesped cell; polypeptide production process; astaxanthin production process from beta-carotene; compositions, products and / or formulations.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006939A (en) * 1957-01-17 1961-10-31 Basf Ag Production of compounds of the betacyclogeranylidene series
DE2653838A1 (en) * 1975-11-30 1977-06-02 Hoffmann La Roche POLYENE COMPOUNDS
US4088689A (en) * 1976-09-15 1978-05-09 Hoffmann-La Roche Inc. Cyclohexenone phosphonium salts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098827A (en) * 1977-01-17 1978-07-04 Hoffmann-La Roche Inc. 1-(2,6,6-Trimethyl-3-hydroxy-1-cyclohexen-1-yl)-3-methyl-penta-1,4-diene[or 1-yn-4-EN]-3-ols
DE2964401D1 (en) * 1978-06-02 1983-02-03 Hoffmann La Roche Process for the preparation of cyclohexenyl derivatives, and intermediates produced in the synthesis
EP0005749B1 (en) * 1978-06-02 1983-03-30 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Derivatives of cyclohexene, process for their peparation, as well as their uses
EP0101597B1 (en) * 1982-08-20 1988-06-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Process for the preparation of astaxanthine and intermediates in the astaxanthine synthesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006939A (en) * 1957-01-17 1961-10-31 Basf Ag Production of compounds of the betacyclogeranylidene series
DE2653838A1 (en) * 1975-11-30 1977-06-02 Hoffmann La Roche POLYENE COMPOUNDS
US4088689A (en) * 1976-09-15 1978-05-09 Hoffmann-La Roche Inc. Cyclohexenone phosphonium salts

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002881A1 (en) * 1992-07-21 1994-02-03 Basf Aktiengesellschaft Polyenes with non-linear optical properties
EP0633258A1 (en) * 1993-07-05 1995-01-11 BASF Aktiengesellschaft Improved process for the production of astaxanthin, new intermediates therefor and a process for their production
CN1052001C (en) * 1993-07-05 2000-05-03 Basf公司 The preparation of astaxanthin, novel intermediates therefor and the preparation thereof
CN1045004C (en) * 1994-03-25 1999-09-08 武田药品工业株式会社 Process for producing carotene compounds

Also Published As

Publication number Publication date
DE4014203A1 (en) 1991-11-07
JPH04225933A (en) 1992-08-14
US5210314A (en) 1993-05-11
EP0455119A3 (en) 1992-04-15

Similar Documents

Publication Publication Date Title
EP0025843B1 (en) Preparation of monoalkyl ethers of hydroxyphenols and their transformation into hydroxycumaranes
DE2801908A1 (en) CYCLOHEXENDERIVATE
EP0455119A2 (en) Process for the preparation of canthaxanthin and astaxanthin
EP0209798B1 (en) Process for the isolation of p-hydroxybenzaldehyde
DE2536504C3 (en) Process for the production of halogen dienes
DE69229459T2 (en) Process for the preparation of keto acids
DE3719622A1 (en) METHOD FOR THE PRODUCTION OF (GAMMA) -HALOGEN-TIGLINIC ACID ALKYL ESTERS AND 0.0-DIALKYL- (GAMMA) -PHOSPHONO-TIGLIN ACID ALKYL ESTERS AND NEW PHOSPHONOESTER DERIVATIVES
EP0052314B1 (en) Preparation of monoalkyl ethers of hydroxyphenols
EP0087585A1 (en) Method for the preparation of 3-alkoxy-acrylonitriles
DE2533396C2 (en) 3-Methyl-3-aryl-pyruvic acid esters and process for their preparation
EP0045425B1 (en) Process for the halogenation of possibly substituted 4-tert.-butyl toluenes and the mixtures obtained therefrom of possibly substituted 4-tert.-butylbenzal halogenides, 4-tert.-butylbenzyl halogenides and 4-tert.-butylbenzo trihalogenides
DE2737299C2 (en) Process for obtaining pure 3-phenoxybenzaldehyde
DE2721265C2 (en) Process for the preparation of di-n-propylacetonitrile
DE10025700A1 (en) Process for the preparation of trifluoroethoxy-substituted benzoic acids
EP0035635B1 (en) Process for the preparation of trimethyl benzoquinone
DE707426C (en) Production of unsaturated aldehydes
DE2729974B2 (en) Process for the preparation of aqueous solutions or finely divided aqueous dispersions of polyenyltriarylphosphonium salts
DE3936399A1 (en) PROCESS FOR PREPARING 1,4-BIS- (4-HYDROXYBENZOYL) -BENZOLE
EP0302331A2 (en) Esters of arylbisperfluoralkylcarbinols, method for the preparation of the same and of the arylbisperfluoralkylcarbinols in question
DE69600519T2 (en) Process for the preparation of tertiary butyl hydrozine halide
DE2361144C3 (en) Sulfon alcohols and their esters and processes for their preparation
DE69514133T2 (en) Process for the preparation of phosphonium salts
EP0705840B1 (en) Process for the preparation of 0,0-dialkyl-4-phosphono-2-methyl-2-butenic acid alkylesters and 4-halogeno-2-methyl-2-butenic acid alkylesters with high content of E-isomers
DE3031385A1 (en) 1-HYDROXYPYRAZOLE AND METHOD FOR THE PRODUCTION THEREOF
EP0361119B1 (en) Process for the production of benzophenones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): CH DE FR GB LI NL

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): CH DE FR GB LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19920818

R18W Application withdrawn (corrected)

Effective date: 19920818